6tvj
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='6tvj' size='340' side='right'caption='[[6tvj]]' scene=''> | <StructureSection load='6tvj' size='340' side='right'caption='[[6tvj]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'> | + | <table><tr><td colspan='2'>Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TVJ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TVJ FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DAR:D-ARGININE'>DAR</scene>, <scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR, 10 models</td></tr> |
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DAR:D-ARGININE'>DAR</scene>, <scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tvj FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tvj OCA], [https://pdbe.org/6tvj PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tvj RCSB], [https://www.ebi.ac.uk/pdbsum/6tvj PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tvj ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tvj FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tvj OCA], [https://pdbe.org/6tvj PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tvj RCSB], [https://www.ebi.ac.uk/pdbsum/6tvj PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tvj ProSAT]</span></td></tr> | ||
</table> | </table> | ||
- | <div style="background-color:#fffaf0;"> | ||
- | == Publication Abstract from PubMed == | ||
- | Peptides are a rapidly growing class of therapeutics with various advantages over traditional small molecules, especially for targeting difficult protein-protein interactions. However, current structure-based methods are largely limited to natural peptides and are not suitable for designing bioactive cyclic topologies that go beyond natural l-amino acids. Here, we report a generalizable framework that exploits the computational power of Rosetta, in terms of large-scale backbone sampling, side-chain composition and energy scoring, to design heterochiral cyclic peptides that bind to a protein surface of interest. To showcase the applicability of our approach, we developed two new inhibitors (PD-i3 and PD-i6) of programmed cell death 1 (PD-1), a key immune checkpoint in oncology. A comprehensive biophysical evaluation was performed to assess their binding to PD-1 as well as their blocking effect on the endogenous PD-1/PD-L1 interaction. Finally, NMR elucidation of their in-solution structures confirmed our de novo design approach. | ||
- | |||
- | Target-templated de novo design of macrocyclic d-/l-peptides: discovery of drug-like inhibitors of PD-1.,Guardiola S, Varese M, Roig X, Sanchez-Navarro M, Garcia J, Giralt E Chem Sci. 2021 Mar 2;12(14):5164-5170. doi: 10.1039/d1sc01031j. PMID:34163753<ref>PMID:34163753</ref> | ||
- | |||
- | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
- | </div> | ||
- | <div class="pdbe-citations 6tvj" style="background-color:#fffaf0;"></div> | ||
- | == References == | ||
- | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
- | [[Category: Synthetic construct]] | ||
[[Category: Garcia J]] | [[Category: Garcia J]] | ||
[[Category: Giralt E]] | [[Category: Giralt E]] | ||
[[Category: Guardiola S]] | [[Category: Guardiola S]] | ||
[[Category: Varese M]] | [[Category: Varese M]] |
Current revision
Solution structure of PD-i3 peptide inhibitor of the human PD-1 extracellular domain
|